Clarivate Launches DRG Fusion - A New Life Sciences Analytics Product Powered by Real-World Data
Rhea-AI Summary
Clarivate (NYSE:CLVT) has launched DRG Fusion, a new analytics platform designed to support commercial analytics in life sciences. The platform integrates real-world data from medical and pharmacy claims to help biopharma and medtech organizations optimize their commercial strategies.
The platform features modular data analytics products with configurable dashboards supporting patient journey analysis, commercial targeting, market access optimization, and patient segmentation. Fusion streamlines data management by providing ready-made visuals and tables to accelerate commercial decisions.
The company plans to introduce AI-driven and self-service features to Fusion in 2025, demonstrating its commitment to delivering user-centric solutions for healthcare challenges.
Positive
- Launch of new analytics platform expanding product portfolio
- Platform addresses growing market need for integrated healthcare data analytics
- Planned AI-driven features expansion in 2025 showing innovation pipeline
Negative
- None.
News Market Reaction 1 Alert
On the day this news was published, CLVT declined 1.57%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
New modular analytics solution empowers commercial teams to optimize strategies and improve patient outcomes
Biopharma and medtech organizations face increasing challenges in extracting insights from fragmented data sources while adapting to competitive pressures and shifting market demands. Fusion addresses these issues by delivering market data and analytics from integrated medical and pharmacy claims and other real-world data sources, empowering life science organizations to create a healthier tomorrow. Its user-tested workflows and on-going data refreshes empower teams to quickly identify gaps in product positioning and uncover opportunities to enhance patient acquisition and retention.
Fusion addresses the critical needs of biopharma and medtech commercial, sales and marketing teams by offering modular data analytics products aligned to functional team needs. Pre-built modules provide users with configurable dashboards to support patient journey analysis, commercial targeting, market access optimization and patient segmentation.
Abeezer Tapia, Senior Vice President & General Manager, Real-World Data, Life Sciences & Healthcare, Clarivate, said: "Fusion is built to harness real-world data in specific ways to help our customers maximize their product value. Its four product workflows cater to specific objectives—be it sizing and segmenting target patient populations, identifying and mitigating leakage points across the patient journey, deploying sales teams based on precise commercial targeting, or designing value messages and assistance programs to optimize access. With data mastered at the drug and device level, Fusion provides the targeted market insights that are critical to inform biopharma and medtech decision-making."
Henry Levy, President, Life Sciences & Healthcare, Clarivate, added: "Fusion demonstrates the robustness of life sciences data from Clarivate and its wide-ranging commercial applications. Its scalable data architecture is carefully designed to rapidly deliver insights across patient diseases and sub-population cohorts. We are committed to investing in innovative technologies that empower our clients to address healthcare's most pressing challenges. With new AI-driven and self-service features set to launch in Fusion in 2025, we remain focused on delivering user-centric solutions that drive meaningful value and impact for our customers."
Fusion streamlines the data management and querying process for life sciences organizations by simplifying complex data analysis with ready-made, informative visuals and tables accelerating commercial decisions.
To learn more about how this modular analytics platform can help organizations optimize their product launch and growth strategies while improving patient outcomes, visit here.
About Clarivate Real-World Data
Clarivate offers a unique blend of products and expert consultancy to support you at every stage of your journey with real-world data (RWD). Our platform seamlessly integrates medical and pharmacy claims, SDoH, mortality and registry data to deliver valuable insights across the development lifecycle. With cohort-specific data tailored to your needs, we provide precise answers to key business questions. Our modular analytics platform, designed by data scientists, epidemiologists, and former clinicians, provides functional insights to enhance your commercial strategy. We also offer expert support in data configuration, advanced ML models, and the integration of disparate datasets to ensure you have the tools and expertise to drive success. Offerings include Clarivate Real-World Data Nucleus, Clarivate Real-World Data Fusion Platform, Clarivate Real-World Data Consulting & Insights and Clarivate Real-World Data Rare Disease Franchise.
About Clarivate
Clarivate™ is a leading global provider of transformative intelligence. We offer enriched data, insights & analytics, workflow solutions and expert services in the areas of Academia & Government, Intellectual Property and Life Sciences & Healthcare. For more information, please visit www.Clarivate.com.
Media Contact:
Catherine Daniel
Director, External Communications, Life Sciences & Healthcare
newsroom@Clarivate.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/clarivate-launches-drg-fusion---a-new-life-sciences-analytics-product-powered-by-real-world-data-302349862.html
SOURCE Clarivate Plc
FAQ
What is DRG Fusion and when did Clarivate (CLVT) launch it?
What are the main features of Clarivate's DRG Fusion platform?
What new features will be added to Clarivate's DRG Fusion in 2025?
How does DRG Fusion benefit biopharma and medtech organizations?
